Astellas US Holding, Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States and operates extensively across North America. Founded in 2005, Astellas has rapidly evolved, focusing on innovative solutions in areas such as oncology, urology, and immunology. The company is renowned for its commitment to research and development, which has led to the creation of unique therapies that address unmet medical needs. With a strong market position, Astellas has achieved significant milestones, including the successful launch of several key products that enhance patient outcomes. The company’s dedication to advancing healthcare through cutting-edge science and patient-centric approaches sets it apart in a competitive landscape. Astellas continues to strive for excellence, making a meaningful impact on global health.
How does Astellas US Holding, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Astellas US Holding, Inc.'s score of 50 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Astellas US Holding, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Astellas Pharma Inc., which may influence its climate commitments and performance metrics. While Astellas US Holding, Inc. does not report its own emissions, it inherits climate initiatives and targets from its parent company, Astellas Pharma Inc. This includes participation in various sustainability frameworks, such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are cascaded from Astellas Pharma Inc. at a corporate family level. Despite the lack of specific emissions data, Astellas Pharma Inc. has made commitments to reduce its carbon footprint and enhance sustainability practices across its operations. The absence of documented reduction targets or specific climate pledges at the subsidiary level suggests that Astellas US Holding, Inc. may align its efforts with the broader strategies set forth by its parent company. In summary, while Astellas US Holding, Inc. does not currently report its own carbon emissions or specific reduction targets, it is part of a corporate structure that prioritises climate action through inherited commitments from Astellas Pharma Inc.
Access structured emissions data, company-specific emission factors, and source documents
2005 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 108,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | - | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | - | - | - | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Astellas US Holding, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.